Scientific paper - Original scientific paper
Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study
European Journal of Clinical Pharmacology, 79 (2023), 5; 643-655. https://doi.org/10.1007/s00228-023-03479-3

Trkulja, Vladimir; Kodvanj, Ivan

Cite this document

Trkulja, V. & Kodvanj, I. (2023). Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study. European Journal of Clinical Pharmacology, 79. (5), 643-655. doi: 10.1007/s00228-023-03479-3

Trkulja, Vladimir and Ivan Kodvanj. "Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study." European Journal of Clinical Pharmacology, vol. 79, no. 5, 2023, pp. 643-655. https://doi.org/10.1007/s00228-023-03479-3

Trkulja, Vladimir and Ivan Kodvanj. "Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study." European Journal of Clinical Pharmacology 79, no. 5 (2023): 643-655. https://doi.org/10.1007/s00228-023-03479-3

Trkulja, V. and Kodvanj, I. (2023) 'Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study', European Journal of Clinical Pharmacology, 79(5), pp. 643-655. doi: 10.1007/s00228-023-03479-3

Trkulja V, Kodvanj I. Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study. European Journal of Clinical Pharmacology [Internet]. 2023 March 24 [cited 2024 October 07];79(5):643-655. doi: 10.1007/s00228-023-03479-3

V. Trkulja and I. Kodvanj, "Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study", European Journal of Clinical Pharmacology, vol. 79, no. 5, pp. 643-655, March 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:402417. [Accessed: 07 October 2024]

Please login to the repository to save this object to your list.